Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Eur J Pharm Biopharm. 2021 Mar 24;163:72–101. doi: 10.1016/j.ejpb.2021.03.010

Fig. 9.

Fig. 9.

a) Schematic showing the fabrication of GO(HPPH)-PEG-HK. b.i, ii, iii, iv) Different regimens of GO(HPPH)-PEG-HK driven PDT in the subcutaneous 4T1 tumor model (i), GO(HPPH)-PEG-HK driven PDT at one tumor model to stimulate immunity at the second tumor (ii), GO(HPPH)-PEG-HK driven PDT to induce the necrotic 4T1 cells to use them for tumor vaccination (iii, iv). c,g) Representative bioluminescence images (c), and quantitative analysis (g). d) Representative images of the lung filled with Indian ink. e, f) Quantitative analysis (e) and H&E staining (f) of metastatic lesions in lungs. h) Representative SPECT/CT images of mice after the 99mTc-αCD8/Fab and 99mTc-IgG/Fab administration and vaccination using PBS and necrotic 4T1 cells, respectively. Adopted with permission from reference [196].